Compare Heron Therapeutics Inc (HRTX) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Match Group Inc — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Match Group Inc trades at $38.8 (market cap $9.10B). The key difference: Match Group Inc is far larger — about 99.5× Heron Therapeutics Inc's market cap, and Match Group Inc pays a 2.05% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MTCH | |
|---|---|---|
Market Cap | $91.46M | $9.10B |
Sector | Health | Media |
52-Week High | $1.96 | $40.29 |
52-Week Low | $0.39 | $28.90 |
Enterprise Value | $189.36M | $12.05B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
MTCH trades at $39.10, down 0.13% today, with a bullish technical outlook supported by moving averages and key resistance at $40. The company reported Q1 2026 revenue growth of 4% but missed EPS expectations. Strong profitability is evident with a 73.8% gross margin and 17.59% net margin. Recent news highlights Tinder's turnaround efforts and Hinge's growth, with Q2 2026 earnings due August 4, 2026.
The stock presents a moderate buy opportunity with a consensus price target of $41.63, offering ~6% upside. Risks include Tinder's user declines and high debt levels, but valuation multiples like a P/E of 14.94 suggest potential undervaluation. Investor sentiment is positive, with no analyst sell ratings, though execution on user growth remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
